- 专利标题: Regulatable chimeric antigen receptor
-
申请号: US16210480申请日: 2018-12-05
-
公开(公告)号: US11578130B2公开(公告)日: 2023-02-14
- 发明人: Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
- 申请人: Novartis AG , The Trustees of the University of Pennsylvania
- 申请人地址: CH Basel; US PA Philadelphia
- 专利权人: Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人: Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人地址: CH Basel; US PA Philadelphia
- 代理机构: K&L Gates LLP
- 优先权: CNPCT/CN2014/082615 20140721,CNPCT/CN2014/090494 20141106
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K31/436 ; A61K35/17 ; C07K14/705 ; C07K14/71 ; C07K14/725 ; C07K14/74 ; C12N9/12 ; C12N9/90
摘要:
Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
公开/授权文献
- US20190263914A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 公开/授权日:2019-08-29
信息查询